New hope for advanced prostate cancer: drug combo trial launches
NCT ID NCT06568094
First seen Nov 18, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This study tests a new drug called HRS-5041, given as a tablet alongside other cancer treatments, for men with advanced prostate cancer. The goal is to see if the combination is safe and helps lower PSA levels, a key marker of cancer activity. About 100 men aged 18 to 80 with good performance status are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiao Tong University School of Medicine, Renji Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact
-
The Second Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, 150000, China
Contact
Conditions
Explore the condition pages connected to this study.